Current Report Filing (8-k)
April 13 2021 - 7:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported) April 9, 2021
Greenwich
LifeSciences, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-39555
|
|
20-5473709
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.
R. S. Employer
Identification No.)
|
3992
Bluebonnet Dr, Building 14
|
Stafford,
TX 77477
|
(Address
of principal executive offices, including ZIP code)
|
|
(832)
819-3232
|
(Registrant’s
telephone number, including area code)
|
|
Not
Applicable
|
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, $0.001 par value
|
|
GLSI
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
On
April 9, 2021, Greenwich LifeSciences, Inc. (the “Company”) issued a press release announcing the abstract results
of the final 5 year immune response data of the Phase IIb clinical trial at the 2021 AACR Annual Meeting (the “AACR Meeting”).
In addition, in April 10, 2021, the Company issued a press release announcing the presentation of a poster of the final 5 year GP2 Phase
IIb clinical trial immune response data at the AACR Meeting.
Copies
of the press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated
herein by reference.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Greenwich
LifeSciences, Inc.
|
|
|
|
Date:
April 13, 2021
|
By:
|
/s/
Snehal Patel
|
|
|
Snehal
Patel
Chief
Executive Officer
|
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Apr 2024 to May 2024
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From May 2023 to May 2024